Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07081503
PHASE1
Phase 1 Study of ADX-626 in Healthy Participants
Sponsor: ADARx Pharmaceuticals, Inc.
View on ClinicalTrials.gov
Summary
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Official title: A Phase 1, Randomized, Blinded, Placebo-Controlled Study to Assess ADX-626 in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2025-08-12
Completion Date
2027-01-22
Last Updated
2026-03-02
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ADX-626
siRNA duplex oligonucleotide
DRUG
Placebo
Saline
Locations (1)
Richmond Pharmacology
London, United Kingdom